A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UC Irvine UCSD UCSF
- Dates
- study startedstudy ends around
- Principal Investigator
- by Farshid Dayyani (uci)Michael Cheng (ucsf)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientists at University of California Health
- Farshid Dayyani (uci)
Clinical Professor, Medicine, School of Medicine. Authored (or co-authored) 87 research publications - Michael Cheng (ucsf)
Dr. Michael L. Cheng is an academic medical oncologist and Assistant Professor at the University of California, San Francisco (UCSF), where he leads clinical and translational research focused on advancing discoveries in cancer genomics and developing improved therapies for thoracic malignancies, especially Non-Small Cell Lung Cancer (NSCLC). Dr. Cheng received his M.D.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Frontier Medicines Corporation
- ID
- NCT06244771
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- Expecting 293 study participants
- Last Updated